ABSTRACT
F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y
INTRODUCTION
For acute ischemic stroke, the clinical benefit of intravenous thrombolysis (IVT) within 4.5 hours and of intra-arterial thrombectomy (IAT) within 6 hours from symptom onset is firmly established. [1] [2] [3] [4] [5] [6] [7] For both IVT and IAT the passing of time is the most crucial factor limiting clinical effectiveness. [8] [9] [10] For example, with every 15 minutes delay to treatment the chances of independent ambulation substantially decrease and one month of disability-free life is lost. [2-6, 8, 11, 12] Moreover, reducing treatment delays will make IVT/IAT accessible for patients who would otherwise exceed the IVT/IAT time window. Therefore, reducing delay to IVT/IAT is of paramount importance. This has been substantiated by guidelines with the door-to-needle time (DNT) for IVT as an important practice and quality parameter, [13, 14] and this will likely transpire for the door-to-groin time (DGT) for IAT as well. [15] Since the introduction of IVT median DNTs have been reduced, but further reduction is still possible. [13] Reducing DGT appears logistically even more challenging. More caregivers are involved and IAT frequently requires inter-hospital transport.
Besides in-hospital delays, prehospital delays should be considered (e.g. time spent on scene by EMS personnel). These delays are often less recognized and have scarcely diminished over the past decades, [16] [17] [18] while relevant time reductions can be achieved. [19] [20] [21] [22] We will further refer to the entire (pre-and in-hospital) treatment trajectory that can be influenced by caregivers and depends on optimal logistics as the 'total system delay' (TSD), in analogy to the literature in cardiology (see From the field of psychology it is well-established that awareness of being observed maximizes dedication and efforts. This so-called 'Hawthorne effect' increases efficacy, and leads to optimal workflow and streamlined care. [24] [25] [26] Cohort studies have shown that feedback to caregivers reduces delays to IVT, [27] [28] [29] but feedback was not provided real-time, prehospital delays were not accounted for and IAT was not standard of care at the time. The literature on feedback as a tool to reduce TSD in patients with acute myocardial infarction is more extensive and shows promising results. [30, 31] For example, in a recent Dutch study real-time visual feedback was associated with a 18-minute reduction in TSD to percutaneous coronary intervention. [32] 
METHODS

Study design A Reduction in Time with Electronic Monitoring In Stroke (ARTEMIS) is a multiregional,
multicentre prospective randomised open-label blinded end-point (PROBE) trial, investigating if realtime audio-visual feedback to caregivers reduces TSD to IVT/IAT. The study is conducted in three both urban and peripheral Emergency Medical Services (EMS) regions, comprising over 2.5 million inhabitants. Each region contains one comprehensive stroke centre with IAT-availability and at least one local hospital treating over 30 IVT-patients per year.
We hypothesize that real-time audio-visual feedback to caregivers on actual TSD will reduce median TSD to IAT with at least 20 minutes, and median TSD to IVT with at least 10 minutes compared with regular care. All patients ≥18 years considered IVT/IAT-eligible by the EMS dispatch office or on-site EMS personnel, following regional EMS' stroke algorithm.
Randomisation
Randomisation of the intervention (real-time audio-visual feedback) will be automatically generated per patient based on a computer algorithm.
Intervention
Real-time audio-visual feedback will be delivered through handhelds and tablets en route from ambulance to IVT/IAT initiation. Real-time visual feedback on actual treatment delays for the transferred patient will be shown to caregivers involved. Also, a colour code (green, orange or red) will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded. Additionally, on pre-set locations (e.g. the Emergency room (ER), computed tomography (CT) room and angiography suite) auditory feedback broadcasting the elapsed time on pre-set moments (e.g. every 3-5 minutes) will be installed.
In order to provide real-time audio-visual feedback we will use an electronic patient tracking system.
For every patient a wristband with a unique ibeacon will be used that automatically activates recording once unwrapped by EMS personnel at the moment the dispatch office issues an ambulance for a potentially IVT/IAT-eligible patient. The ibeacon emits a low-voltage Bluetooth signal, which will be automatically picked up by fixed handhelds in the ambulance and pre-mounted in-hospital tablets en route to IVT/IAT providing accurate, straightforward and automatic data on TSD and its various sub trajectories (see Figure 2) . TSD ends at the moment IVT/IAT is initiated. For TSD to IVT this is the moment the bolus of F o r p e e r r e v i e w o n l y 6 alteplase is administered, whereas the endpoint for TSD to IAT will be groin-puncture and the last angio-run. These endpoints will be registered automatically once a fixed button in the CTroom/neuro-care unit or angiography suite is pushed. This will be verified for every IVT/IAT-treated patient with the Electronic Patient Recording (EPR). All recordings on patient tracking are automatically stored in a protected cloud.
Other data including demographics, medical history, EMS parameters, physical and additional test results and interventional features performed as part of standard care will be documented anonymously from the EPR.
As soon as possible after admission, the patient or legal representative will be informed on the study and a deferred consent will be signed.
Patients are allowed to refuse the wristband application without any consequences. Subjects can leave the study at any time for any reason if they wish to do so without any consequences.
Primary outcomes
TSD to IAT and TSD to IVT (minutes).
Secondary outcomes
1. TSD sub trajectories: ambulance arrival at 'scene-of-stroke', time spent on scene, 'scene-of-stroke'-to-hospital time, arrival and departure from the ER, CT room, neuro-care unit, and angiography suite.
2. Proportion of patients treated with IVT/IAT, of all acute ischemic stroke patients presented to the ER within 4.5 hours (IVT) / 6 hours (IAT) after symptom onset. [13] 3. Functional outcome (modified Rankin Scale) at three months, [33] evaluated through a standardized and validated telephone interview by an observer blinded to treatment allocation. 
Data Monitoring Body
No data safety monitoring board will be installed since the trial yields no risks for participating subjects.
Sample size estimates
Sample size calculation is based on the hypothesis of an at least 20-minute reduction of TSD to IAT and an at least 10 minute reduction of TSD to IVT. We think these reductions are feasible based on data from MR CLEAN. [2] In the MR CLEAN trial (n=500), mean TSD to IAT (n=233) was 256 minutes (SD 40). To detect a 20-minute difference with a p-value of 0.05, and a power of 0.8 we will need 63 patients in each arm.
To increase power, we aim at including 75 IAT-patients in each arm.
In the MR CLEAN trial mean TSD for IVT was 90 minutes (SD 35). To detect a 10-minute difference of TSD to IVT with a p-value of 0.05, and a power of 0.8 we will need 193 IVT-patients in each arm.
In clinical practice approximately 9% of patients for whom the dispatch office issues an ambulance will end up being treated with IVT [19] . Of these patients approximately 30% will be eligible for IAT [2] . Therefore we expect that for the inclusion of 150 IAT-patients EMS personnel will have to unpack a wristband approximately 5000 times over an estimated study period of two years.
During a run-in phase we will electronically collect additional data on treatment delays (without providing feedback to caregivers) to adjust sample size calculation if required.
Statistical analyses
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   8 For all analyses involving time intervals, differences in time delays between randomization groups will be calculated with corresponding 95% confidence intervals. We will perform subgroup analysis for IAT-patients with-or without prior IVT, and for patients within-and out of office hours. We will use linear regression analysis, with additional log-transformation if appropriate, to adjust for EMS region and for treatment location as this is expected to affect TSD to IVT/IAT. If required we will adjust for differences in EMS response-and transfer times due to geographically different locations of stroke. Through additional regression analysis we will assess a possible effect of calendar time on TSD and whether such an effect is group-dependent.
The total number of times the EMS dispatch office issues an ambulance will be used to calculate the proportion of patients with a discharge diagnosis of stroke and the total number of IVT/IAT-treated patients in each group. IVT/IAT-treated patients lacking endpoint registration will be excluded from primary endpoint analysis. Exploratory analysis will be performed to relate TSD to clinical outcome in each group.
Additionally, we will perform cost-effective analysis of the electronic tracking system including the feedback intervention.
DISCUSSION
With ARTEMIS we aim to reduce TSD to IVT/IAT with an innovative and straightforward intervention: real-time audio-visual feedback to caregivers.
The PROBE design is pragmatic and reflects standard clinical practice of acute stroke care. By using automatically generated primary outcomes (TSD to IVT/IAT; i.e. time) study results are as valid as those derived from a double-blind placebo controlled trial. [35] We anticipate that during the study period treatment delays will decrease due to initiatives aimed to optimize logistics other than our intervention. Moreover, data accrual on treatment delays by itself could already be an incentive to optimize logistics. For example, DNTs reduced substantially after
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Another possible bias is that the intervention effect will carry-over to controls. Since shifts of treatment teams generally occur multiple times a day we think this is unlikely. Nevertheless, analyses to elucidate trends over time will be performed.
Also, since TSD registration depends on the unwrapping of patient wristbands, starting times of electronic registration will be checked with automatic time logs of the ambulance.
Finally, a potential limitation is that study results on TSD will particularly be applicable to areas similar to the Netherlands, with a highly concentrated network of hospitals and a relatively short 'scene of stroke'-to-hospital distance. We expect in-hospital results to be more widely generalizable.
SUMMARY AND CONCLUSIONS
Reducing treatment delays for acute stroke relies on team effort between various caregivers in both pre-and in-hospital trajectories. This will always carry an inherent risk that a chain is only as strong as its weakest link. Meanwhile, the total trajectory is what matters most to the patient, as neuronal death in stroke is critically time dependent.
[38] The intervention we investigate embodies the whole chain of acute stroke care, from patient's first EMS contact to start of treatment. Thus, with our intervention we can establish a unique connection between various acute stroke team members who nowadays mainly work separately.
Because we do not exclude any (sub)groups of suspected stroke patients and our study population encompasses both urban as peripheral areas, the ARTEMIS trial has great external validity. In addition, the introduced technique will likely also benefit other (neurological and non-neurological) patient groups for whom clinical benefits of treatment are time dependent.
With the introduction of real-time audio-visual feedback through an electronic patient tracking system we expect treatment delays to become more transparent, to improve workflow, to reduce TSD to IVT/IAT, resulting in improved clinical outcomes and a larger proportion of acute ischemic stroke patients eligible for treatment with IVT/IAT.
ETHICS AND DISSEMINATION
The ARTEMIS trial is approved by the Medical Ethics Committee of Leiden University Medical Centre (reference: NL 56747.058.016). Participating centres will have access to their own results and collective study results will be disseminated through peer-reviewed journals and (inter)national conferences. writing of the report; and the decision to submit the report for publication. Endpoint registration will take place through fixed real-life push buttons.
abbreviations: CAT room = catheterization room, CT = computed tomography, ER = Emergency Room, IAT = intra-arterial thrombectomy, IVT = intravenous thrombolysis, TSD = total system delay IVT, within-or out of office hours and EMS region will be performed.
With 75 IAT-and 225 IVT-patients in each arm we will be able to demonstrate a 20-minute difference in TSD to IAT and a 10-minute difference in TSD to IVT (p=0.05 and power=0.8).
Ethics and dissemination
The ARTEMIS trial is approved by the Medical Ethics Committee of Leiden University Medical
Centre. Study findings will be disseminated through peer-reviewed journals and (inter)national conference presentations.
Trial registration clinicaltrials.gov identifier: NCT02808806 (registered June 14, 2016).
KEY WORDS: acute ischemic stroke, intravenous thrombolysis, intra-arterial thrombectomy, time to treatment, treatment delay, total system delay Strengths and limitations of this study:
• ARTEMIS is a multiregional, multicentre, randomised trial providing high external validity.
• The intervention establishes a unique connection in the chain of acute stroke care bridging the gap between separate pre-and in hospital caregivers involved.
• The PROBE design is pragmatic and reflects standard clinical practice of acute stroke care.
• We anticipate that during the study period treatment delays will decrease due to initiatives aimed to optimize logistics other than our intervention.
• A carry-over effect of the intervention cannot be fully excluded but is estimated to be unlikely since shifts of stroke teams occur multiple times a day. 
INTRODUCTION
Besides in-hospital delays, prehospital delays should be considered (e.g. time spent on scene by EMS personnel). These delays are often less recognized and have scarcely diminished over the past decades, [16] [17] [18] while relevant time reductions can be achieved. [19] [20] [21] [22] We will further refer to the entire (pre-and in-hospital) treatment trajectory that can be influenced by caregivers and depends on optimal logistics as the 'total system delay' (TSD), in analogy to the literature in cardiology (see
Figure 1).[23]
A promising method to reduce TSD is to provide real-time audio-visual feedback to caregivers directly involved with the patient. With our study, we aim to determine the efficacy of real-time audio-visual feedback on TSD to IVT/IAT in patients presenting with acute ischemic stroke. We hypothesize that real-time audio-visual feedback to caregivers on actual TSD will reduce median TSD to IAT with at least 20 minutes, and median TSD to IVT with at least 10 minutes compared with regular care. 
METHODS
Intervention
Real-time audio-visual feedback will be delivered through handhelds and tablets en route from ambulance to IVT/IAT initiation. Real-time visual feedback on actual treatment delays for the transferred patient will be shown to caregivers involved. Also, a colour code (green, orange or red)
will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded. Additionally, on pre-set locations (e.g. the Emergency room (ER), computed tomography (CT) room and angiography suite) auditory feedback broadcasting the elapsed time on pre-set moments (e.g. every 3-5 minutes) will be installed.
For every patient a wristband with a unique ibeacon will be used that automatically activates recording once unwrapped by EMS personnel at the moment the dispatch office issues an ambulance for a potentially IVT/IAT-eligible patient. The ibeacon emits a low-voltage Bluetooth signal, which will be automatically picked up by fixed handhelds in the ambulance and pre-mounted in-hospital tablets en route to IVT/IAT providing accurate, straightforward and automatic data on TSD and its various sub trajectories (see Figure 2) .
TSD ends at the moment IVT/IAT is initiated. For TSD to IVT this is the moment the bolus of alteplase is administered, whereas the endpoint for TSD to IAT will be groin-puncture and the last angio-run. These endpoints will be registered automatically once a fixed button in the CTroom/neuro-care unit or angiography suite is pushed by the treating physician. This will be verified for every IVT/IAT-treated patient with the Electronic Patient Recording (EPR). All recordings on patient tracking are automatically stored in a protected cloud. As soon as possible after hospital admission, the patient or legal representative will be informed on the study and a deferred consent will be obtained by a local investigator.
Randomisation
Randomisation of the intervention (real-time audio-visual feedback) will be automatically generated per patient based on a computer algorithm. This will be prior to EMS distribution of (randomised)
ibeacons.
Primary outcomes TSD to IAT and TSD to IVT (minutes).
Secondary outcomes 1. TSD sub trajectories: ambulance arrival at 'scene-of-stroke', time spent on scene, 'scene-of-stroke'-to-hospital time, arrival and departure from the ER, CT room, neuro-care unit, and angiography suite.
2. Proportion of patients treated with IVT/IAT, of all acute ischemic stroke patients presented to the ER within 4.5 hours (IVT) / 6 hours (IAT) after symptom onset. [13] 3. Functional outcome (modified Rankin Scale) at three months, [33] evaluated through a standardized and validated telephone interview by an observer blinded to treatment allocation. (a) occurrence of symptomatic intracerebral haemorrhage defined as evidence of intracranial haemorrhage on imaging associated with neurological deterioration (an increase in NIHSS of ≥4 points) or death. [34] NIHSS is routinely performed by the treating physician and will otherwise be constructed from medical records as described previously. [35] (b) proportion of IVT/IAT-treated stroke mimics.
Data Monitoring Body
Patient and Public Involvement
For the purpose of this study a focus group advising in design, implementation and effectuation of the study (including patients' associations, nurses, health care insurers, PDEng clinical informatics) was created. Next to publications in peer-reviewed journals, a public symposium is planned to disseminate study results to patients and other interested parties.
Sample size estimates
Sample size calculation is based on the hypothesis of an at least 20-minute difference of TSD to IAT and an at least 10 minute difference of TSD to IVT. We think these differences are feasible based on data from MR CLEAN. [2] In the MR CLEAN trial (n=500), mean TSD to IAT (n=233) was 256 minutes (SD 40). To detect a 20-minute difference with a p-value of 0.05, and a power of 0.8 we will need 63 patients in each arm. In clinical practice approximately 9% of patients for whom the dispatch office issues an ambulance will end up being treated with IVT.
[19] Of these patients approximately 30% will be eligible for IAT.
[2] Therefore we expect that for the inclusion of 150 IAT-patients EMS personnel will have to unpack a wristband approximately 5000 times over an estimated study period of two years.
Statistical analyses
For all analyses involving time intervals, differences in time delays between randomisation groups will be calculated with corresponding 95% confidence intervals. Analyses will be performed on an intention-to-treat basis. We will perform subgroup analysis for IAT-patients with-or without prior IVT, for patients within-and out of office hours, and for EMS region. We will use linear regression analysis, with additional log-transformation if appropriate, to adjust for cluster effect of EMS region and for treatment location as this is expected to affect TSD to IVT/IAT. If required we will adjust for differences in EMS response-and transfer times due to geographically different locations of stroke.
Through additional regression analysis we will assess a possible effect of calendar time on TSD and whether such an effect is group-dependent.
Although randomisation is computerized and by chance, baseline differences may still arise between the two groups with possible effect on outcome measures. For this reason we will collect data on other determinants of TSD (e.g. NIHSS, time from onset of symptoms, drip-and-ship vs. mothership), and we will adjust for possible baseline incomparability.
The total number of times the EMS dispatch office issues an ambulance will be used to calculate the proportion of patients with a discharge diagnosis of stroke and the total number of IVT/IAT-treated Additionally, we will perform cost-effective analysis of the electronic tracking system including the feedback intervention.
DISCUSSION
The PROBE design and the open nature of our intervention is pragmatic and reflects future clinical practice of acute stroke care. By using automatically generated primary outcomes (TSD to IVT/IAT;
i.e. time) study results are as valid as those derived from a double-blind placebo controlled trial. [36] We anticipate that during the study period treatment delays will decrease due to initiatives aimed to optimize logistics other than our intervention. Moreover, data accrual on treatment delays by itself could already be an incentive to optimize logistics. For example, DNTs reduced substantially after these became transparent.[37, 38] However, we do not expect this to invalidate our results as reduction of DNT took considerably longer than the intended length of our study. Besides, such an effect would be notable in both groups. Nonetheless, we will compare available treatment delays before and after the start of ARTEMIS.
Also, since TSD registration depends on the unwrapping of patient wristbands and pushing a fixed button, starting times of electronic registration will be checked with automatic time logs of the ambulance, and endpoint registration will be cross-checked with the EPR. In addition, we think that We anticipate that the intention to speed up the logistic process with real-time audio-visual feedback could theoretically lead to more stroke mimics being treated with IVT, which for this reason is one of our safety outcomes. More importantly, this could potentially lead to more haemorrhagic complications related to IVT/IAT (another safety outcome). However, we think this is an inherent risk related to treatment of acute stroke patients, already starting before caregivers are involved by mass media campaigns to educate the public to respond rapidly to a stroke (e.g. Face-Arm-Speech-Time).
Moreover, with each (existent and new) intervention aimed to reduce treatment delays the acute stroke team should work as fast as possible while remaining diagnostic accuracy. In addition, this theoretical danger is not reflected in current practice, as shortening door-to-needle times, for example, did not to lead to an increased number of other safety parameters such as symptomatic intracerebral haemorrhages.
[39] As for stroke mimics, a recent meta-analysis showed that IVT treatment in this group appears to be safe.
[40] Nevertheless, since it is possible that treatment of stroke mimics may occur in our population, for a valid TSD comparison, we will perform subgroup analysis on TSD in patients in which diagnosis of ischaemic stroke and treatment have been confirmed.
Also, more patients being treated with IVT and/or IAT within the 4.5 (IVT) or 6 hour (IAT) time window could potentially increase mean TSD. Nonetheless, we think that in parallel to this the proportion of treated patients within the early intervals of these time windows will also increase, minimizing such an effect.
[41] The intervention we investigate embodies the whole Because we do not exclude any (sub)groups of suspected stroke patients and our study population encompasses both urban as peripheral areas, the ARTEMIS trial has great external validity.
Another important strength of ARTEMIS is the introduction of an innovative, accurate and straightforward technique that automatically provides healthcare professionals with data on important performance measures of acute stroke care that are currently often collected retrospectively in a time consuming effort at the expense of accuracy.
In addition, the introduced technique will likely also benefit other (neurological and non-neurological) patient groups for whom clinical benefits of treatment are time dependent.
CONCLUSION
STATUS OF STUDY
First recruitment was February 15 th 2018. Up to this moment, 63 patients received an ARTEMIS wristband.
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